The NeurologyLive® Narcolepsy Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the sleep disorder.
May 8th 2024
Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.
Prioritizing Sleep Health in the Modern World of Sleep Disorders: Ana Krieger, MD, MPH
April 1st 2024The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]
Changing the Perception of Narcolepsy to Reduce Stigma: Mark I. Boulos, MD, MSc, FRCP, CSCN
January 11th 2024The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, discussed recent research that challenged the conventional definitions of sleep and how narcolepsy is often stigmatized. [WATCH TIME: 2 minutes]
Once-Nightly Sodium Oxybate Effective in Both Narcolepsy Type 1 and 2
December 16th 2023Subgroups of narcolepsy types 1 and 2 had significant reductions in a number of secondary outcomes, including number of sleep stage transitions, number of nocturnal arousals, and improvements in sleep quality.
Evaluating Positive Phase 1 Trial Data for Narcolepsy Agent ALKS 2680
November 11th 2023Brendon Yee, PhD, a respiratory and sleep physician at the Woolcock Institute of Medical Research, discussed findings from a recent phase 1 trial presented at World Sleep Congress 2023 in which ALKS 2680 demonstrated improvements in wakefulness among patients with narcolepsy type 1.
Preclinical Data Shows Significant Efficacy With Low-Dose of ORX750 for Narcolepsy
October 31st 2023Presented at the 2023 World Sleep Congress, preclinical findings highlighted ORX750's potential as a novel treatment not only for narcolepsy type 1 but also for broader sleep-wake disorders, including narcolepsy type 2 and idiopathic hypersomnia.
Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men
October 30th 2023A recent study assessing TAK-861, an orexin-type 2 receptor agonist, high and lose doses of the therapy demonstrated improvements in wakefulness compared with the placebo in healthy adult men.
Addressing Unmet Needs of Narcolepsy Beyond Medication
October 24th 2023Nancy Foldvary-Schaefer, DO, FAAN, director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, discussed the recent advancements in narcolepsy treatments and the importance of incorporating a holistic care approach for patients.
The Significance of Normal Mean Sleep Latency in Diagnosing Narcolepsy
October 17th 2023Mark I. Boulos, MD, BSc, FRCP, CSCN, MSc, associate professor of medicine, division of neurology, Institute of Medical Science, University of Toronto, talked about a comprehensive meta-analysis aimed to determine normal mean sleep latency values to accurately help clinicians with interpreting sleep test results.
Role of Sleep Coaching, Sleep Reset in the Care of Sleep Problems
October 6th 2023Michael Grandner, PhD, associate professor of psychiatry at the University of Arizona College of Medicine, discussed Sleep Reset, an app-based, personalized sleep program that uses sleep coaches to help guide patients in the care of their sleep disorders.
Novel Insights on Orexin Receptor TAK-994 and its Discontinued Narcolepsy Study
October 4th 2023Elena Koundourakis, PhD, head of orexin franchise development at Takeda, talked about the phase 2 trial investigating TAK-994 in patients with narcolepsy type 1, which showed significant improvements in wakefulness, despite discontinuation because of hepatotoxicity.